ArticleMedical hypotheses2020
What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Integrated renin angiotensin system dysregulation and immune profiles predict COVID-19 disease severity in a South African cohort.Scientific reports · 2025Article
- Human plasma kallikrein: roles in coagulation, fibrinolysis, inflammation pathways, and beyond.Frontiers in physiology · 2023Review
- Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches.Chemico-biological interactions · 2022Article
- Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- COVID-19 and Lung Mast Cells: The Kallikrein-Kinin Activation Pathway.International journal of molecular sciences · 2022Article
- Impaired Kallikrein-Kinin System in COVID-19 Patients' Severity.Frontiers in immunology · 2022Observational
- COVID-19-Associated Cardiovascular Complications.Diseases (Basel, Switzerland) · 2021Review
- Targeted LC-MS/MS platform for the comprehensive determination of peptides in the kallikrein-kinin system.Analytical and bioanalytical chemistry · 2021Article
- Diagnostic accuracy of symptoms as a diagnostic tool for SARS-CoV 2 infection: a cross-sectional study in a cohort of 2,173 patients.BMC infectious diseases · 2021Observational
- COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.Molecular biology reports · 2021Review
- Kinins and chymase: the forgotten components of the renin-angiotensin system and their implications in COVID-19 disease.American journal of physiology. Lung cellular and molecular physiology · 2021Review
- Sensitive mass spectrometric determination of kinin-kallikrein system peptides in light of COVID-19.Scientific reports · 2021Article
- Mathematical Model of SARS-Cov-2 Propagation Versus ACE2 Fits COVID-19 Lethality Across Age and Sex and Predicts That of SARS.Frontiers in molecular biosciences · 2021Article
- Review
- Interactions amongst inflammation, renin-angiotensin-aldosterone and kallikrein-kinin systems: suggestive approaches for COVID-19 therapy.The journal of venomous animals and toxins including tropical diseases · 2021Review
- Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review.Journal of clinical medicine · 2020Review
- Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: A case series of 306 Mediterranean patients.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Article
- Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.Expert review of clinical pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is an infectious disease with fast spreading all over the world caused by the SARS-CoV-2 virus which can culminate in a severe acute respiratory syndrome by the injury caused in the lungs. However, other organs can be also damaged. SARS-CoV-2 enter into the host cells using the angiotensin-converting enzyme 2 (ACE2) as receptor, like its ancestor SARS-CoV. ACE2 is then downregulated in lung tissues with augmented serum levels of ACE2 in SARS-CoV-2 patients. Interestingly, ACE2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.